Noncommercial US Funders’ Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability | Zendy

Evelyn P Whitlock | Zendy; Kelly M. Dunham | Zendy; Kimberly DiGioia | Zendy; Emily Lazowick | Zendy; Theresa Gleason | Zendy; David Atkins | Zendy

Open Access

Noncommercial US Funders’ Policies on Trial Registration, Access to Summary Results, and Individual Patient Data Availability

Author(s) -

Evelyn P Whitlock,

Kelly M. Dunham,

Kimberly DiGioia,

Emily Lazowick,

Theresa Gleason,

David Atkins

Publication year - 2019

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.7498

Subject(s) - transparency (behavior) , data sharing , business , clinical trial , public relations , political science , medicine , public health , family medicine , alternative medicine , nursing , pathology , law

Key Points Question What are the current policies for clinical trial registration, summary results sharing, and individual patient data sharing among the top 10 noncommercial US health research funders? Findings In this review study, 6 of 9 (67%) of the top US funders have a publicly available written policy addressing all 3 major trial transparency domains. However, fewer US funders require specific transparency actions in these domains (11%-56%) or monitor compliance with their policies (56%-67%). Meaning More work remains to be done to ensure timely implementation and enforcement of clinical trial transparency initiatives to reduce waste and realize public value from clinical research investments.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research